Market News & Trends
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating its Next-Generation Vaccine Candidates Elicit Mucosal & Systemic Immunogenicity & Reduce Viral Shedding After SARS-CoV-2 Challenge
Vaxart, Inc. recently announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of…
Studies Validate Advantages of Administering Drugs to Pets Via IntelGenx’s VetaFilm Platform
IntelGenx Corp. recently announced positive results from a proof-of-concept (POC) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm…
Biovian & 3P Biopharmaceuticals Join Forces to Create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), recently announced their combination to establish a new pan-European leader in their….
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Ltd. recently announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment…
Denali Therapeutics Announces Presentations on its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies
Denali Therapeutics Inc. recently announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at…
Ascendia Pharmaceuticals Expanding Injectable Manufacturing Capabilities in 2024
Ascendia Pharmaceuticals is all set to unveil its new injectables manufacturing opportunities with the launch of a state-of-the-art sterile cGMP production facility in March 2024…..
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Kindeva Drug Delivery recently announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to…
BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
Cristalia Products With Nemera’s Reusable Pen Injector Commercialized in Brazil
Cristalia’s human growth hormone will be administered with CRISPEN. Approved by ANVISA1, CRISPEN is part of Nemera’s state-of-the-art pen injector platform PENDURA AD……..
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc recently announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil…
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases With University of Florida
Vaxxinity, Inc. recently announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on…
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved With Potential First-in-Class Oral Treatment for PKU
Jnana Therapeutics recently announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor…
Oxford Biomedica Completes Acquisition of ABL Europe
The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens….
Longeveron Receives Notice of US Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B
Longeveron Inc. recently announced it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs),…
First Patient Dosed With LIXTE’s LB-100 & GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
LIXTE Biotechnology Holdings, Inc. recently announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s…
GDMC Secures $21-Million Growth Capital Funding to Expand Global Genetic Medicines Design & Manufacturing Operations
Genetic Design and Manufacturing Corporation (GDMC) recently announced a Series A funding of $21 million. The funding round is led by Celadon Partners, an Asia…
Repare Therapeutics Announces Achievement of $40-Million Roche Clinical Milestone Payment
Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial….
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients With Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. recently announced the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap). From the…
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients With Rheumatoid Arthritis
Incannex Healthcare Inc. recently announced patient dosing has commenced in the Phase 2 clinical trial assessing IHL-675A in patients with rheumatoid arthritis (RA). IHL-675A is…
